| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/30/2022 | -0.61% | Barclays | → $23 | Initiates Coverage On | → Equal-Weight |
| 09/14/2022 | 64.22% | JMP Securities | $35 → $38 | Maintains | Market Outperform |
| 09/12/2022 | 116.08% | HC Wainwright & Co. | $46 → $50 | Maintains | Buy |
| 09/02/2022 | 72.86% | Stifel | → $40 | Initiates Coverage On | → Buy |
| 08/09/2022 | 98.79% | HC Wainwright & Co. | $47 → $46 | Maintains | Buy |
| 06/06/2022 | -43.82% | Jefferies | → $13 | Initiates Coverage On | → Underperform |
| 05/24/2022 | 81.5% | Goldman Sachs | $49 → $42 | Maintains | Buy |
| 05/10/2022 | 103.11% | HC Wainwright & Co. | $54 → $47 | Maintains | Buy |
| 05/09/2022 | 51.25% | JMP Securities | $50 → $35 | Maintains | Market Outperform |
| 02/01/2022 | 94.47% | Berenberg | → $45 | Initiates Coverage On | → Buy |
| 08/17/2021 | 133.36% | HC Wainwright & Co. | $57 → $54 | Maintains | Buy |
| 07/21/2021 | 116.08% | B of A Securities | → $50 | Initiates Coverage On | → Buy |
| 01/29/2021 | 124.72% | JP Morgan | $36 → $52 | Maintains | Neutral |
| 12/15/2020 | 146.33% | HC Wainwright & Co. | $54 → $57 | Maintains | Buy |
| 12/08/2020 | 185.22% | JMP Securities | → $66 | Initiates Coverage On | → Market Outperform |
| 11/05/2020 | 133.36% | HC Wainwright & Co. | → $54 | Initiates Coverage On | → Buy |
Relay Therapeutics Questions & Answers
The latest price target for Relay Therapeutics (NASDAQ: RLAY) was reported by Barclays on September 30, 2022. The analyst firm set a price target for $23.00 expecting RLAY to fall to within 12 months (a possible -0.61% downside). 10 analyst firms have reported ratings in the last year.
The latest analyst rating for Relay Therapeutics (NASDAQ: RLAY) was provided by Barclays, and Relay Therapeutics initiated their equal-weight rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Relay Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Relay Therapeutics was filed on September 30, 2022 so you should expect the next rating to be made available sometime around September 30, 2023.
While ratings are subjective and will change, the latest Relay Therapeutics (RLAY) rating was a initiated with a price target of $0.00 to $23.00. The current price Relay Therapeutics (RLAY) is trading at is $23.14, which is out of the analyst's predicted range.